3rd Apr 2018 13:25
He will be replacing Robin Campbell, who will become a non-executive director with immediate effect after more than one and a half years in the role since October 2016.
Feldmann currently shares the academic credit for inventing and developing anti-TNF therapy for rheumatoid arthritis, the first major use of monoclonal antibodies in a common disease.
Feldmann is currently an Emeritus Professor at the University of Oxford.
"I am delighted that after eight months as chairman of our Scientific Advisory Board, Sir Marc has agreed to join us as chairman. I know that Sir Marc shares our enthusiasm for developing transformational therapies for bone marrow and blood stem cell transplants that will have a major impact on the way we routinely treat lethal blood diseases. Since Sir Marc has been at the forefront of promoting effective scientific-medical-pharmaceutical interactions, he has built up a huge network of friends and collaborators who meet regularly in Oxford and they will help Hemogenyx grow and go clinical," said Chief Executive Officer Vladislav Sandler.
Shares in Hemogenyx Pharmaceuticals were up 4.6% at
Related Shares:
Hemogenyx